Biotech Values

[DewDiligence]

From ABBV’s PR:

17p deletion is found in 3-10% of previously untreated cases and up to 30-50% percent of relapsed or refractory cases.

http://finance.yahoo.com/news/abbvie-receives-fda-accelerated-approval-203100094.html

The phrase “up to 30-50%” is a non sequitur, but I suppose the people who write PRs aren’t the brightest.